Hongjiang Qiao

Prof. Dr. Hongjiang Qiao


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJiaoling Chen
Jiaoling Chen
YByaxing Bai
yaxing Bai
KXKe Xue
Ke Xue
ZLZhiguo Li
Zhiguo Li
ZZZhenlai Zhu
Zhenlai Zhu
SSShuai Shao
Shuai Shao
Neutrophils have a pathogenic function in inflammation via releasing pro-inflammatory mediators or neutrophil extracellular traps (NETs). However, their heterogeneity and pro-inflammatory mechanisms remain unclear. Here, we demonstrate that CXCR4hi neutrophils accumulate in the blood and inflamed skin in human psoriasis, and correlate with disease severity. Compared to CXCR4lo neutrophils, CXCR4hi neutrophils have enhanced NETs formation, phagocytic function, neutrophil degranulation, and overexpression of pro-inflammatory cytokines and chemokines in vitro. This is accompanied by a metabolic shift in CXCR4hi neutrophils toward glycolysis and lactate release, thereby promoting vascular permeability and remodeling. CXCR4 expression in neutrophils is dependent on CREB1, a transcription factor activated by TNF and CXCL12, and regulated by de novo synthesis. In vivo, CXCR4hi neutrophil infiltration amplifies skin inflammation, whereas blockade of CXCR4hi neutrophils through CXCR4 or CXCL12 inhibition leads to suppression of immune responses. In this work, our study identifies CREB1 as a critical regulator of CXCR4hi neutrophil development and characterizes the contribution of CXCR4hi neutrophils to vascular remodeling and inflammatory responses in skin.

16 December 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CZChen Zhang
Chen Zhang
ZZZhenlai Zhu
Zhenlai Zhu
JGJiXin Gao
JiXin Gao
LYLuTing Yang
LuTing Yang
EDErLe Dang
ErLe Dang
MFMeng Fu
Meng Fu
Circulating exosomal miR-375-3p promotes keratinocyte apoptosis via XIAP repression in Stevens-Johnson syndrome and toxic epidermal necrolysis.

1 February 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JMJingyi Ma
Jingyi Ma
JCJiaoling Chen
Jiaoling Chen
KXKe Xue
Ke Xue
CYChen Yu
Chen Yu
EDErle Dang
Erle Dang
SSShuai Shao
Shuai Shao

1 June 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
ZZZhenlai Zhu
Zhenlai Zhu
JCJiaoling Chen
Jiaoling Chen
YLYiting Lin
Yiting Lin
CZChen Zhang
Chen Zhang
WLWei Li
Wei Li
GWGang Wang
Gang Wang

6 June 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LLLiang Li
Liang Li
SSShengxian Shen
Shengxian Shen
SSShuai Shao
Shuai Shao
EDErle Dang
Erle Dang
GWGang Wang
Gang Wang
HQHongjiang Qiao
Hongjiang Qiao
The B cell-activating factor (BAFF) system, comprising two ligands and three receptors, plays a pivotal role in adaptive and innate immunity, driving autoimmunity through dysregulated B and T cell survival, differentiation, and cytokine production. This review synthesizes evidence linking BAFF system overexpression to multiple autoimmune diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS), bullous pemphigoid (BP), pemphigus vulgaris (PV), and alopecia areata (AA), where elevated BAFF system molecule levels correlate with autoantibody titers, disease activity, and post-B cell depletion relapse. BAFF-targeted therapies have demonstrated efficacy in reducing disease activity in SLE and SS. Key challenges include interspecies receptor expression discrepancies and context-dependent signalling cascades. Emerging strategies, such as sequential therapy with rituximab followed by belimumab, show promise in treating refractory autoimmune diseases such as BP and PV by counteracting the post-depletion BAFF surge. Despite progress, mechanistic gaps in BAFF-mediated crosstalk between innate and adaptive immunity, as well as interspecies-specific pathogenesis warrant further investigation using humanized disease models and single-cell transcriptomic profiling. This review underscores the therapeutic potential of BAFF system modulation while advocating for disease-specific clinical trials to optimize precision-therapeutic targeting in autoimmune diseases.

20 November 2020 in Chinese Medical Journal
Verified
Journal Article
Open access
CXChun-Ying Xiao
Chun-Ying Xiao
ZZZhenlai Zhu
Zhenlai Zhu
CZChen Zhang
Chen Zhang
MFMeng Fu
Meng Fu
HQHongjiang Qiao
Hongjiang Qiao
EDErle Dang
Erle Dang
Background Psoriasis is a common chronic inflammatory skin disease with 2% to 3% prevalence worldwide and a heavy social-psychological burden for patients and their families. As the exact pathogenesis of psoriasis is still unknown, the current treatment is far from satisfactory. Thus, there is an urgent need to find a more effective therapy for this disease. Keratin 17 (K17), a type I intermediate filament, is overexpressed in the psoriatic epidermis and plays a critical pathogenic role by stimulating T cells in psoriasis. Therefore, we hypothesized that inhibiting K17 may be a potential therapeutic approach for psoriasis. This study aimed to investigate the therapeutic effect of K17-specific small interfering RNA (siRNA) on mice with imiquimod (IMQ)-induced psoriasis-like dermatitis. Methods Eight-week-old female BALB/c mice were administered a 5% IMQ cream on both ears to produce psoriatic dermatitis. On day 3, K17 siRNA was mixed with an emulsion matrix and applied topically to the left ears of the mice after IMQ application every day for 7 days. The right ears of the mice were treated in parallel with negative control (NC) siRNA. Inflammation was evaluated by gross ear thickness, histopathology, the infiltration of inflammatory cells (CD3+ T cells and neutrophils) using immunofluorescence, and the expression of cytokine production using real-time quantitative polymerase chain reaction. The obtained data were statistically evaluated by unpaired t-tests and a one-way analysis of variance. Results The severity of IMQ-induced dermatitis on K17 siRNA-treated mice ears was significantly lower than that on NC siRNA-treated mice ears, as evidenced by the alleviated ear inflammation phenotype, including decreased ear thickness, infiltration of inflammatory cells (CD3+ T cells and neutrophils), and inflammatory cytokine/chemokine expression levels (interleukin 17 [IL-17], IL-22, IL-23, C-X-C motif chemokine ligand 1, and C-C motif chemokine ligand 20) (P < 0.05 vs. the Blank or NC siRNA groups). Compared to the NC siRNA treatment, the K17 siRNA treatment resulted in increased K1 and K10 expression, which are characteristic of keratinocyte differentiation (vs. NC siRNA, K17 siRNA1 group: K1, t = 4.782, P = 0.0050; K10, t = 3.365, P = 0.0120; K17 siRNA2 group: K1, t = 4.104, P = 0.0093; K10, t = 4.168, P = 0.0042; siRNA Mix group: K1, t = 3.065, P = 0.0221; K10, t = 10.83, P < 0.0001), and decreased K16 expression, which is characteristic of keratinocyte proliferation (vs. NC siRNA, K17 siRNA1 group: t = 4.156, P = 0.0043; K17 siRNA2 group: t = 2.834, P = 0.0253; siRNA Mix group: t = 2.734, P = 0.0250). Conclusions Inhibition of K17 expression by its specific siRNA significantly alleviated inflammation in mice with IMQ-induced psoriasis-like dermatitis. Thus, gene therapy targeting K17 may be a potential treatment approach for psoriasis.